I listened to conversation on the most recent conference call referring to more studies and review of the current data. I did not hear any firm dates for any specific catalyst on this call however that is subject to change as we know from these plays.
The most recent PR below and the commentary is of particular interest to me.
"We designed these Phase 2a pilot clinical trials to guide the future development of AZX100 in multiple scarring indications. The favorable safety profile and the observed efficacy signals support our belief that AZX100 is a viable candidate in dermal scar reduction," said Randolph C. Steer, MD, PhD, President of Capstone Therapeutics. "The pattern of AZX100 efficacy at 1.0 mg per linear cm at earlier time points that was seen in the keloid trial will assist us in future dose and administration optimization clinical trials."
"We believe the AZX100 clinical data merit its continued development," said Jock Holliman, Executive Chairman of Capstone Therapeutics. "Based on the results obtained thus far from these Phase 2a pilot clinical trials, Capstone will seek a collaboration partner to advance AZX100 in both surgical and keloid scar reduction."
It is my opinion with management acquiring shares that we have more information coming sometime in the future.
News 
Market Data 
Discover 
AI
